Polski Bank Komórek Macierzystych (PBKM) continues its consolidation efforts in the cord-blood banking in Europe. It holds a c 40% share of the European stem-cell banking market in terms of processed cord blood samples. The market is expected to grow at a double-digit rate globally (Grand View Research) through increased penetration of the service. PBKM has been also involved in 10 clinical trials in stem-cell research, acts as a contract manufacturing organisation and runs a one-day clinic.
Polski Bank Komórek Macierzystych (PBKM) continues its consolidation efforts in the cord-blood banking in Europe. It holds a c 40% share of the European stem-cell banking market in terms of processed cord blood samples. The market is expected to grow at a double-digit rate globally (Grand View Research) through increased penetration of the service. PBKM has been also involved in 10 clinical trials in stem-cell research, acts as a contract manufacturing organisation and runs a one-day clinic.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Polski Bank Komórek Macierzystych (PBKM) continues its consolidation efforts in the cord blood banking services market in Europe. It operates 15 stem cell banks under the FamiCord brand, covering approximately 37% of the European market for newly acquired samples, seeing space for further growth in Western Europe. PBKM is present in 11 European countries, with partners in a further 13 regions. Recent steady growth (2015–19 revenue CAGR of 16%) has been fuelled by both organic development and M&A...
Polski Bank Komórek Macierzystych (PBKM) continues its consolidation efforts in the cord blood banking services market in Europe. It operates 15 stem cell banks under the FamiCord brand, covering approximately 37% of the European market for newly acquired samples, seeing space for further growth in Western Europe. PBKM is present in 11 European countries, with partners in a further 13 regions. Recent steady growth (2015–19 revenue CAGR of 16%) has been fuelled by both organic development and M&A...
• We are positive about stock markets. Stocks ↑ • WIG > EM > SPX > EuroStoxx • The global economic cycle is close to the inflection point. • Central banks’ policy will support risky assets. • GPW is in the ‘risk search’ phase and a wave of optimism may have a dynamic impact on multiple re-rating. • The most important topic for 2020 on the GPW will be a significant increase in the capacity of domestic investors to purchase stocks. Inflows should send valuations up. • Poland:...
Polski Bank Komórek Macierzystych (PBKM) is benefiting from market consolidation of cord blood banking services in Europe. It operates 14 stem cell banks cobranded under the FamiCord umbrella, covering one-third of the European market for newly acquired samples. Recent steady growth (2014–18 revenue CAGR of 17%) has been fuelled by both organic development and M&A. Further substantial acquisitions would require additional capital. The share price has stabilised at PLN62 – the price of the f...
It is worth paying attention to... FINANCIALS + PEO / BHW: We recommend going overweight on banks with high dividend, for which the current DY exceeds 6%. In the scenario of no events in the sector depleting the Bank Guarantee Fund’s funds, these banks should be beneficiaries of the change in the structure of contributions for the next year. In the long run, they may strengthen their position in the sector if the CHF risk becomes large. (Maciej Marcinowski, p. 34/26) + PZU: The Management Boa...
It is worth paying attention to... BANKS + PKO: Another quarter of very good results. Only for PKO, our annual forecast deviates positively from the consensus. The Bank will probably pay out realistically 90% dividend starting next year. Moreover, CHF-denominated loans pose less risk than indexed loans. (Maciej Marcinowski, p. 36) + BHW: We find a 6% DY in a temporarily weak year in terms of results (write-offs for Kania) attractive, especially following recent drops in bond yields. The absence...
It is worth paying attention to: BANKS + PKO: Another quarter of very good results. This year’s stock price is worse than WIG Banks and we can see the potential for reversal of this trend. The Bank wishes to leave 50% of its 2018 profit undistributed, which will enable it to increase the dividend next year. (MM, p. 36) + MIL: Good results despite the upcoming acquisition of Eurobank. Quick synergies can be achieved after the acquisition through replacing the expensive financing of Eurobank. I...
It is worth paying attention to: BANKS + PKO: Another quarter of very good results. This year’s stock price is worse than WIG Banks and we can see the potential for reversal of this trend. The Bank wishes to leave 50% of its 2018 profit undistributed, which will enable it to increase the dividend next year. (MM, p. 36) + MIL: Good results despite the upcoming acquisition of Eurobank. Quick synergies can be achieved after the acquisition through replacing the expensive financing of Eurobank. I...
• Short term: positive attitude. Shares ↑, EM>DM, WIG20WIG20 • WIG20: S-T +10%; L-T WIG20 • Our thesis is that the market is currently in an ‘unreasonably cheap’ phase and we are only just ahead of a phase of doubt, especially in the segment of small companies. • The economic cycle is already behind its peak phase. • The upcoming slowdown will be a classic recession rather than a crisis. • Poland: slowdown in growth, especially in 2H19; strong consumption maintained (although s...
Below we present a summary of meetings with companies during the Trigon BioTech & LifeSciences Day conference held on 27 September 2018. The meetings were attended by the following companies: Celon Pharma, Mabion, Selvita, OncoArendi Therapeutics, PBKM, Synektik, InfoSCAN, Scope Fluidics, Medinice, Pure Biologics and Captor Therapeutics.
Three Directors at Polski Bank Komorek Macierzystych S.A. bought 2,686 shares at between 56.000PLN and 61.480PLN. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.